Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience

Table 5 Risk group distribution before and after mpMRI of the prostate

	Clinical staging	Relative upward shift by mpMRI	Relative downward shift by mpMRI	mpMRI staging
Low-risk group	14 (11.5%)	57.1%	n.a.	7 (5.7%)
Intermediate-risk group	52 (42.6%)	30.8%	0%	44 (36.1%)
High-risk group	53 (43.4%)	13.2%	5.7%	59 (48.4%)
Nodal metastases (cN1)	3 (2.5%)	0%	33.3%	9 (7.4%)
Distant metastases (cM1)	0	n.a.	n.a.	3 (2.5%)

Risk groups for patients (n = 122) were defined according to the National Comprehensive Cancer Network prostate cancer guidelines based on T stage, serum PSA level and the Gleason score derived from prostate biopsy. n.a. = not available.

ISSN: 1748-717X